Bronchodilating beta-agonist compositions and methods
View Patent ↗Bronchodilating compositions and methods are provided. The compositions are intended for administration as a nebulized aerosol. In certain embodiments, the compositions contain formoterol, or a derivative thereof. Methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders using the compositions provided herein are also provided.
1. A method of oral administration comprising the steps of:
(a) adding to a nebulizer, from a propellant-free, sterile unit dose package about 0.1 to about 3.0 mL of a pharmaceutical composition comprising (R) formoterol or a salt thereof at a concentration of from about 0.08 μg/mL to about 43 μg/mL based on formoterol free base, in a pharmacologically suitable solution, wherein the composition further comprises water and a buffer having a concentration of from about 1 mM to about 50 mM, said composition having a pH of about 4.0 to about 6.0, and having an estimated shelf life of greater than 90% after 3 months storage at 25° C. and after 3 years storage at 5° C.; and
(b) directly administering said composition to a subject in need thereof, without dilution or other modification of said prior to administration.
2. A method of oral administration comprising the steps of:
(a) adding to a nebulizer from a propellant-free, sterile unit dose package about 0.1 to about 3.0 mL of a pharmaceutical composition comprising (R) formoterol or a salt thereof at a concentration of from about 0.08 μg/mL to about 43 μg/mL based on formoterol free base, in a pharmacologically suitable solution, wherein the composition further comprises water and a buffer having a concentration of from about 1 mM to about 50 mM, said composition having a pH of about 4.0 to about 6.0, and having an estimated shelf life of greater than about 94% after 3 months storage at 25° C. and greater than about 96% after 3 months storage at 5° C.; and
(b) directly administering said composition to a subject in need thereof, without dilution or other modification of said prior to administration.
3. A method of oral administration comprising the steps of:
(a) adding from a propellant-free, sterile unit dose package to a nebulizer about 0.1 to about 3.0 mL of a pharmaceutical composition comprising (R) formoterol or a salt thereof at a concentration of from about 0.08 μg/mL to about 43 μg/mL based on formoterol free base, in a pharmacologically suitable solution, wherein the composition further comprises water and a citrate buffer at a concentration of from about 1 mM to about 20 mM, said composition having a pH of about 4.5 to about 5.5; and
(b) directly administering said composition to a subject in need thereof, without dilution or other modification of said composition prior to administration.
4. The method of oral administration as in any one of claims 1 , 2 and 3 wherein said undesired and/or uncontrolled bronchoconstriction is a symptom or condition of asthma.
5. The method of oral administration as in any one of claims 1 , 2 and 3 wherein said undesired and/or uncontrolled bronchoconstriction is a symptom or condition of chronic obstructive pulmonary disease.
6. The method of oral administration as in any one of claims 1 , 2 and 3 wherein said buffer is present at a concentration of between about 1 mM and about 50 mM.
7. The method of oral administration as in any one of claims 1 and 2 wherein said buffer is present at a concentration of between about 1 mM and about 20 mM.
8. The method of oral administration as in any one of claims 1 , 2 and 3 wherein said composition has a pH of about 5.
9. The method of oral administration of claim 8 wherein said buffer has a pH of about 5.
10. The method of oral administration as in any one of claims 1 and 2 , wherein about 2.0 mL of the composition is nebulized.
11. The method of oral administration as in any of claims 1 , 2 or 3 , wherein said (R) formoterol or a salt thereof is (R) formoterol tartrate.